

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :C07D 205/12, C07C 229/48
C12P 41/00, 13/04

A1

(11) International Publication Number:

WO 92/18477

(43) International Publication Date:

29 October 1992 (29.10.92)

(21) International Application Number: PCT/GB92/00731

(22) International Filing Date: 21 April 1992 (21.04.92)

(30) Priority data:

9108384.0

19 April 1991 (19.04.91)

GB

(71) Applicant (for all designated States except US): CHIROS LIMITED [GB/GB]; Science Park, Milton Road, Cambridge CB4 4WE (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EVANS, Christopher, Thomas [GB/GB]; Stable Cottage, Fowlmere Road, Heydon, Hertfordshire SG8 8PU (GB). ROBERTS, Stanley, Michael [GB/GB]; Combe Cottage, Slittercombe Lane, Kinton, Devon EX6 8NH (GB). SUTHERLAND, Alan, Gordon [GB/GB]; 7 Taddyforde Court Mansions, New North Road, Exeter EX4 4AS (GB).


(74) Agent: GILL JENNINGS & EVERY; 53/64 Chancery Lane, London WC2A 1HN (GB).

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.


Published

With international search report.


(54) Title: AZABICYCLOHEPTANONE




(Ia)



(Ib)



(IIa)



(IIb)

(57) Abstract

The individual enantiomers of the bicyclic β -lactam compounds (Ia), (Ib), (IIa) or (IIb), optionally substituted by non-interfering substituent(s). The novel enantiomers can be obtained by biotransformation. The Ia or IIa compounds can be used for the synthesis of chiral cis-pentacin.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark			US	United States of America

1
AZABICYCLOHEPTANONE

Field of the Invention

This invention relates to bicycloheptanes, their preparation, and their use as chiral synthons.

5 Background of the Invention

Oki *et al*, J. Antibiotics 42 (1989) 1756, disclose the anti-fungal microbial antibiotic cis-pentacin, of formula III (see below).

10 This compound can be prepared by hydrolysis of the β -lactam (IIa) which may in turn be made by catalytic hydrogenation of the unsaturated β -lactam (Ia).

A preparation of III in optically-active form is described by Korushi *et al*, J. Antibiotics 42 (1989) 1749, involving repeated crystallisation of the (+)-dehydro
15 abietylamine salt formed from the racemate. It is not expected that this represents an economic method of making more than gram quantities of the optically-active antibiotic.

20 EP-A-0424064 describes the enantioselective hydrolysis of the γ -lactam 2-azabicyclo[2.2.1]hept-5-en-3-one, utilising enzymatic activity available in deposits NCIMB 40213 and 40249. See also Taylor *et al*, J. Chem. Soc. Chem. Comm. (1990) 1120. As described by Evans *et al*, J. Chem. Soc. Perkin Trans. I (1991) 656, the cells used for
25 that γ -lactam are apparently intolerant of structural variation.

Summary of the Invention

This invention concerns the enantiomers of azabicycloheptane derivatives of formulae Ia, Ib, IIa and
30 I Ib which, in optically pure form, are novel compounds. They may each be provided substantially free of other enantiomers.

The novel compounds are useful as intermediates to optically-pure biologically-active compounds; in
35 particular, preparation of cis-pentacin from an optically-pure β -lactam precursor (Ia) or (IIa) is advantageous.

Description of the Invention

An important discovery behind the present invention is that material of biological origin will react selectively on racemates of the β -lactam (Ia + Ib) or (IIa + IIb) to
5 give one enantiomer as untransformed lactam recoverable by solvent extraction, and the other as hydrolysis product, i.e. the amino-acid; the amino-acid is retained in aqueous solution upon extraction with solvent, but may be isolated, if required, for instance by adsorption on an ion-exchange
10 resin.

Suitable activities for the enantioselective transformation are described in EP-A-0424064, e.g. those present in certain novel wild-type isolates of the genera Pseudomonas, Alcaligenes, Arthrobacter, Brevibacterium,
15 Nocardia, Rhodococcus and Corynebacterium, whilst not being limited to isolates of these genera. Selection for these activities may be conducted in the presence of compounds containing one or more N-acyl substituents. If necessary, elevated levels of activity may be produced by growth of
20 cells in the presence of such compounds. Particular examples of suitable activity are those produced maximally active in cells of the unique strains ENZA-20 and Rhodococcus sp. ENZA-1, the latter when cultivated in a suitable medium in the presence of N-acetyl-L-phenylalanine or N-acetyl-D,L-phenylalanine.
25

Rhodococcus sp. ENZA-1 was isolated from soil samples by enrichment culture in mineral salts medium containing N-acetyl-L-phenylalanine as the sole source of carbon and energy. The isolate has been deposited at the NCIMB in
30 Aberdeen, on 17.10.89. The accession number is NCIMB 40213.

Although the novel biotransformation is analogous to that described previously, and in EP-A-0424064, the enantioselective hydrolysis of the γ -lactam 2-azabicyclo-
35 [2.2.1]hept-5-en-3-one, efficient transformation of the β -lactam (Ia + Ib) was unexpected, considering that the

cells used for the γ -lactam seemed intolerant of structural variation.

The racemic unsaturated β -lactam (Ia + Ib) is made by the known method of [2+2]cycloaddition of chlorosulphonyl isocyanate onto cyclopentadiene, followed by hydrolytic removal of the chlorosulphonyl function with sodium sulphate. This synthesis is described by Malpass *et al*, J.Chem.Soc.Perkins Trans. I (1977) 874. For the preparation of cis-pentacin it can be advantageous to proceed via the racemic saturated β -lactam (IIa + IIb), for this can be made in an efficient cycloaddition between cyclopentene and chlorosulphonyl isocyanate.

The enantiomers of formulae Ib and IIb are useful synthons in the preparation of β -lactams, cis-pentacin analogues and amino-acid isosteres.

The compounds of the invention may be substituted, if desired, by non-interfering substituents, i.e. substituents that do not affect the biotransformation. Examples of substituents (if present) are methyl, ethyl, n-butyl, OH, Cl, Br, F, CF₃ and N₃. The total number of C atoms in the substituent(s) will not usually exceed 8 or, more usually, 4.

The following Examples illustrate the invention. In each case, the ee value obtained exceeds 99%.

Example 1 Whole cell resolution of 6-azabicyclo[3.2.0]hept-3-en-7-one

Rhodococcus equi NCIB 40213 (ENZA-1; 700 mg paste) was suspended in phosphate buffer (0.05 M; pH 7) and racemic 6-azabicyclo[3.2.0]hept-3-en-7-one (340 mg, 3.12 mmol) was added. The mixture was stirred at ambient temperature for 142 h after which the cells were removed by centrifugation. The supernatant was extracted with dichloromethane (4 x 100 ml) and the combined organic layers were dried (MgSO₄) and concentrated. The recovered lactam (197 mg) was reincubated with ENZA-1 (280 mg) in buffer (36 ml) for a further 170 h, then recovered as above. Column chromatography over silica using acetate as eluent gave

(1R,2S)-(+)-6-azabicyclo[3.2.0]hept-3-en-7-one (137 mg, 40%) as a white solid; m.p. 76-77°C; $[\alpha]_D^{20}$ 37 (c = 0.4, CHCl₃); ν_{\max} (CHCl₃) 3414 and 1754 cm⁻¹; δ_H (CDCl₃) 6.25 (1 H, br s, NH), 6.12-5.85 (2 H, m, 3-H and 4-H), 4.59-4.42 (1 H, m, 5-H), 3.85 (1 H, ddd, J 9.8, 3.5, 3.5 Hz, 1-H) and 2.90-2.25 (2 H, m, 2-H₂).


The strain ENZA-1 thus gave, from the racemic β -lactam (Ia + Ib), the [1R,5S]-(+)-lactam (Ia) in >99% ee and 40% yield together with an amino-acid of opposite configuration which was isolated as its methyl ester, acetamide, in 96% ee. The recovered lactam (Ia) was of the correct stereochemistry for conversion into (-)-cis-pentacin.

Example 2 Hydrogenation of (1R,2S)-(+)-6-azabicyclo[3.2.0]-hept-3-en-7-one


The title lactam (57 mg, 0.52 mmol) in ethyl acetate (3 ml) was added to a suspension of 10% palladium on charcoal (8 mg) in ethyl acetate (2 ml). The mixture was stirred under hydrogen at ambient temperature for 1½ h. when Hc indicated complete reaction (on silica, eluent ethyl acetate, KMnO₄ development, product has R_f 0.38, starting material has R_f 0.45). The mixture was filtered through Celite and the filtrate concentrated to a colourless oil (55 mg 95%) which solidifies below room temperature. It was pure by GC and ¹H NMR; $[\alpha]_D$ -38 (c = 1.1, CHCl₃).

Example 3 cis-pentacin


The reduced lactam from Example 2 (53 mg, 0.48 mmol) was stirred in 2 M hydrochloric acid (6 ml) at ambient temperature for 1 h when Hc indicated complete reaction (silica, ethyl acetate:methanol 4:1, KMnO₄ development). The mixture was loaded onto a Dowex (H⁺) column and eluted with water followed by 1 M aqueous ammonia. Fractions containing product were concentrated to give cis-pentacin [(1R,2S)-2-aminocyclopentane-1-carboxylic acid] (60 mg, 97%) as an off-white solid $[\alpha]_D$ -8 (c = 1, H₂O).




Ia




Ib



IIa




IIb



III

CLAIMS

1. The individual enantiomers of the bicyclic β -lactam compounds (Ia), (Ib), (IIa) or (IIb),



optionally substituted by non-interfering substituent(s).


2. A process for the resolution of a mixture enantiomers of bicyclic β -lactams (Ia + Ib) or (IIa + IIb) as defined in claim 1, by means of a biocatalyst derived from bacterial whole cells and characterised by its ability to hydrolyse only one enantiomer of the mixture, to give the corresponding ring-opened amino-acid.

3. Use of an enantiomer (Ia) or (IIa) as defined in claim 1, for the synthesis of the anti-fungal antibiotic cis-pentacin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/00731

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07D205/12; C07C229/48; C12P41/00; C12P13/04		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; C07C ; C12P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	THE JOURNAL OF ANTIBIOTICS vol. 42, no. 12, 1989, pages 1749 - 1755; KONISHI ET AL.: 'CISPENTACIN, A NEW ANTIFUNGAL ANTIBIOTIC.' cited in the application see the whole article, especially page 1753, scheme 2 ---	1-3
A	JOURNAL OF THE CHEMICAL SOCIETY PERKIN TRANSACTIONS 1 no. 3, March 1991, pages 656 - 657; C. EVANS ET AL.: 'SYNTHESIS OF EITHER ENANTIOMER OF CIS-3-AMINOCYCLOPENTANECARBOXYLIC ACID FROM BOTH ENANTIOMERS OF RACEMIC 2-AZABICYCLO (2.2.1) HEPT-5-EN-3 ONE.' cited in the application see the whole article --- -/--	1-3
<p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
30 JUNE 1992	10. 07. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	CHOULY J. 	

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	TETRAHEDRON LETTERS no. 27, 1972, pages 2793 - 2796; H. REHLING ET AL.: 'CIRCULARDICHROISMUS UND ABSOLUTE KONFIGURATION VON BETA-LACTAMEN' see the whole article, especially page 2795, table 2, nr. 13 ---	1
P,X	JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1 no. 9, September 1991, pages 2276 - 2277; C. EVANS ET AL.: 'WHOLE CELL CATALYSED KINETIC RESOLUTION OF 6-AZABICYCLO(3.2.0)HEP-3-EN-7-ONE: SYNTHESIS OF (-)-CISPENTACIN (FR 109615).' see the whole article ---	1-3
P,A	EP,A,0 424 064 (ENZYMATIX LTD.) 24 April 1991 cited in the application see claims ---	1-3

58488

.30/06/92

EPO FORM 0009

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)